| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10911240 | Lung Cancer | 2013 | 7 Pages |
Abstract
This retrospective analysis found that the co-administration of AS and erlotinib did not appear to have a significant impact on the median plasma drug levels or outcome.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
J.F. Hilton, D. Tu, L. Seymour, F.A. Shepherd, P.A. Bradbury,